Genome Insight, a San Diego, CA-based Whole Genome Sequence analysis and interpretation company, raised $23 in Series B funding.
The round was led by Dunamu & Partners with participation from InterVest, Signite Partners, KC, and VNTG Corporation, as well as existing investors DSC Investment, Paratus Investment, and Schmidt.
The company intends to use the funding to advance its data production and curation pipelines that enable scalable investigation of whole-genome sequences (WGS).
Founded in 2020 in South Korea by co-founders Young Seok Ju and Jeong Seok Lee, who are both physician-scientists and professors at KAIST (Korea Advanced Institute of Science and Technology), Genome Insight is a whole genome sequence (WGS) analysis and interpretation company. Its proprietary GINS platform is an automated WGS pipeline and computer system that can rapidly generate meaningful interpretation insights for clinicians and patients, making WGS data useable in real-life clinical settings.
WGS examines the entire genomic sequence of diseased tissues, providing comprehensive characterization of tens of thousands of genomic mutations carried on it as a whole.
The company is also actively engaged in research to promote the power of WGS in advancing novel therapeutic strategies for cancer and rare diseases.
Genome Insight is headquartered in San Diego (US) with the R&D offices in Seoul and Daejeon (Korea).
FinSMEs
01/05/2022